Supplier Blow-Out

Products can't wait

Although big-ticket spending may have softened in the discovery space, product companies that loaded up on cash last year have a different story to tell, saying that their clinical and marketing programs must be driven forward, regardless of macroeconomics and the bear market for biotech stocks.

"We don't expect to curtail our spending level," said Nancy Chang, CEO of antibody play Tanox Inc., which has the luxury of having raised $244.2 million in its March 2000 IPO.